All Pathways
Internal MedicineManagement

Hypothyroidism Management (ATA Guidelines)

Hypothyroidism Management (ATA Guidelines): Suspected Hypothyroidism → Initial Workup → TSH Result → Overt Hypothyroidism → Levothyroxine Dosing.

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Suspected Hypothyroidism

    Fatigue, cold intolerance, constipation, weight gain

    1. Action

      Initial Workup

      TSH is primary screening test

      • TSH (most sensitive)
      • Free T4 if TSH abnormal
      • TPO antibodies if etiology unclear
      1. Decision

        TSH Result

        Interpret with free T4

        • High TSH, low FT4 = overt hypothyroidism
        • High TSH, normal FT4 = subclinical
        • Normal TSH = euthyroid
        1. Action

          Overt Hypothyroidism

          TSH elevated, FT4 low

          • Treat with levothyroxine
          • Initial dose: 1.6 mcg/kg/day (full replacement)
          • Start lower in elderly/CAD: 25-50 mcg/day
          • Take on empty stomach, AM
          1. Action

            Levothyroxine Dosing

            Age and cardiac status matter

            • Young healthy: 1.6 mcg/kg/day
            • Elderly or CAD: start 12.5-25 mcg/day
            • Increase by 12.5-25 mcg q4-6 weeks
            • Brand consistency recommended
            1. Action

              Monitoring

              TSH follow-up

              • Recheck TSH 6-8 weeks after dose change
              • Goal TSH: 0.5-2.5 mIU/L for most
              • Higher TSH ok in elderly (up to 6-8)
              • Once stable: annual TSH
              1. Action

                TSH Still Elevated

                Increase dose or address adherence

                • Increase by 12.5-25 mcg
                • Check adherence (timing, empty stomach)
                • Drug interactions: calcium, iron, PPI
                • Malabsorption (celiac, GI surgery)
              2. Outcome

                TSH at Goal

                Continue current dose

                • Annual TSH monitoring
                • Dose may need adjustment:
                • - Weight changes
                • - Pregnancy
                • - Age >65 (may need less)
              3. Warning

                TSH Suppressed (<0.5)

                Over-replacement

                • Risk: AFib, osteoporosis
                • Reduce dose by 12.5-25 mcg
                • Recheck in 6-8 weeks
                • Exception: thyroid cancer suppression
        2. Decision

          Subclinical Hypothyroidism

          TSH elevated, FT4 normal

          • TSH 4.5-10: repeat in 6-12 weeks
          • TSH >10: consider treatment
          • Treat if: symptomatic, TPO+, pregnancy desired
          1. Action

            Treat Subclinical

            If criteria met

            • Start low: 25-50 mcg/day
            • Lower threshold to treat if:
            • - Symptoms present
            • - TPO antibodies positive
            • - TSH >10
            • - Pregnancy or planning
          2. Action

            Observe Subclinical

            If mild and asymptomatic

            • Recheck TSH in 6-12 months
            • May normalize spontaneously
            • Treat if worsens or develops symptoms
        3. Outcome

          Euthyroid (Normal TSH)

          No thyroid disease

          • Consider non-thyroid causes of symptoms
          • No further thyroid workup needed

Guideline Source

Guidelines for the Treatment of Hypothyroidism (ATA/AACE)

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Does not cover subclinical hypothyroidism in detail
  • Pregnancy hypothyroidism needs OB input
  • Central hypothyroidism requires specialist evaluation
  • Does not address myxedema coma (emergency)
  • Drug dosing requires individualization

Applicable Regions

USEU

EU: ETA guidelines similar

US: Based on ATA guidelines

Version 1Next review: 2027-01-11

Frequently Asked Questions

What is the Hypothyroidism Management (ATA Guidelines)?

The Hypothyroidism Management (ATA Guidelines) is a management clinical algorithm for Internal Medicine. It provides a structured decision tree to guide clinical decision-making, based on Guidelines for the Treatment of Hypothyroidism (ATA/AACE).

What guideline is the Hypothyroidism Management (ATA Guidelines) based on?

This algorithm is based on Guidelines for the Treatment of Hypothyroidism (ATA/AACE) (DOI: 10.1089/thy.2014.0028).

What are the limitations of the Hypothyroidism Management (ATA Guidelines)?

Known limitations include: Does not cover subclinical hypothyroidism in detail; Pregnancy hypothyroidism needs OB input; Central hypothyroidism requires specialist evaluation; Does not address myxedema coma (emergency); Drug dosing requires individualization. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Hypothyroidism Management (ATA Guidelines) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free